budesonide; formoterol fumarate; glycopyrrolate - Profile

What are the generic sources for budesonide; formoterol fumarate; glycopyrrolate and what is the scope of freedom to operate?

Budesonide; formoterol fumarate; glycopyrrolate is the generic ingredient in one branded drug marketed by Astrazeneca Ab and is included in one NDA. There are nine patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Budesonide; formoterol fumarate; glycopyrrolate has two hundred and nineteen patent family members in thirty-five countries.

Summary for budesonide; formoterol fumarate; glycopyrrolate

International Patents:	219
US Patents:	9
Tradenames:	1
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for budesonide; formoterol fumarate; glycopyrrolate

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for budesonide; formoterol fumarate; glycopyrrolate

Constraining patent/regulatory exclusivity:

NEW STRENGTH

Dosage:

AEROSOL, METERED;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

US Patents and Regulatory Information for budesonide; formoterol fumarate; glycopyrrolate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	8,815,258
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	8,703,806
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	8,808,713		Y
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	8,324,266
Astrazeneca Ab	BREZTRI AEROSPHERE	budesonide; formoterol fumarate; glycopyrrolate	AEROSOL, METERED;INHALATION	212122-001	Jul 23, 2020		RX	Yes	Yes	9,415,009

International Patents for budesonide; formoterol fumarate; glycopyrrolate

Country	Patent Number	Title	Estimated Expiration
Argentina	076621
Argentina	076806
Argentina	076807
Argentina	121758
Argentina	122477

Supplementary Protection Certificates for budesonide; formoterol fumarate; glycopyrrolate

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2435024	202140009	Slovenia		PRODUCT NAME: COMBINATION OF FORMOTEROL (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF), GLYCOPYRROLATE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF) AND BUDESONIDE (INCLUDING ANY PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS, SOLVATES OR ENANTIOMERS THEREOF); NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF NATIONAL AUTHORISATION: 20201209; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2435024	301102	Netherlands		PRODUCT NAME: COMBINATIE VAN FORMOTEROL (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN), GLYCOPYRROLAAT (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN) EN BUDESONIDE (MET INBEGRIP VAN DE FARMACEUTISCH AANVAARDBARE ZOUTEN, ESTERS, SOLVATEN OF ENANTIOMEREN ERVAN); REGISTRATION NO/DATE: EU/1/20/1498 20201210
2435024	C202130025	Spain		PRODUCT NAME: UNA COMBINACION DE FORMOTEROL ( INCLUIDAS SUS SALES, ESTERES, SOLVATOS O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES I, GLICOPIRROLATO ( INCLUIDAS SUS SALES, ESTERES, SOLVATOS O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES ) Y BUDESONIDA ( INCLUIDAS SUS SALES, ESTERES, SOLVATOS O ENANTIOMEROS FARMACEUTICAMENTE ACEPTABLES ).; NATIONAL AUTHORISATION NUMBER: EU/1/20/1498; DATE OF AUTHORISATION: 20201209; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1498; DATE OF FIRST AUTHORISATION IN EEA: 20201209
2435024	2021019	Norway		PRODUCT NAME: KOMBINASJON AV FORMOTEROL; REG. NO/DATE: EU/1/20/1498 20201216
2435024	CA 2021 00014	Denmark		PRODUCT NAME: KOMBINATION AF FORMOTEROL, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, GLYCOPYRROLAT, HERUNDER ALLE FARMACEUTISK ACCEPTABLE SALTE, ESTERE, SOLVATER ELLER ENANTIOMERE DERAF, OG BUDESONID, HERUNDER...; REG. NO/DATE: EU/1/20/1498 20201210

Investment Scenario, Market Dynamics, and Financial Trajectory for Budesonide, Formoterol Fumarate, and Glycopyrrolate

Last updated: February 3, 2026

Executive Summary

This report provides a comprehensive analysis of the investment potential, market dynamics, and expected financial trajectory of the combination therapy comprising budesonide, formoterol fumarate, and glycopyrrolate. The combination, primarily targeted towards respiratory conditions such as chronic obstructive pulmonary disease (COPD) and asthma, is positioned within a rapidly expanding pharmaceutical market driven by rising prevalence, regulatory approvals, and technological advancements. Through critical examination of market drivers, competitive landscape, regulatory environment, and financial forecasts, this analysis offers strategic insights for investors considering exposure to this therapeutic niche.

---

Market Overview: Key Components and Therapeutic Indications

Active Ingredient	Indication	Formulation Types	Development Stage
Budesonide	Asthma, COPD	Inhalers (MDI, DPI), nebulizers	Commercially available
Formoterol Fumarate	COPD, Asthma	DPI, MDI	Commercially available
Glycopyrrolate	COPD (maintenance), RBD (rare)	Inhalation, injectable	Approved, in market

Source: Market intelligence reports and product labeling (FDA, EMA approvals).

Therapeutic Focus

• Budesonide: An inhaled corticosteroid with anti-inflammatory effects.
• Formoterol Fumarate: A long-acting beta-agonist (LABA), providing bronchodilation.
• Glycopyrrolate: A long-acting muscarinic antagonist (LAMA), reducing airway constriction.

Market Dynamics Influencing Investment

1. Market Size and Growth

Region	2022 Market Size (USD Billion)	CAGR (2022-2027)	Projected 2027 Market Size (USD Billion)
North America	8.2	4.7%	10.2
Europe	4.5	4.3%	5.6
Asia-Pacific	3.8	7.8%	6.7
Rest of World	1.2	4.5%	1.4
Total	17.7	5.2%	23.9

Note: Driven by rising COPD and asthma prevalence, aging populations, and advancements in inhalation device technology (IQVIA, 2023).

2. Epidemiological Drivers

• COPD prevalence: Estimated at 300 million worldwide, projected to increase due to smoking and pollution.
• Asthma prevalence: Affects approximately 262 million globally (WHO, 2018).
• Treatment penetration: Underdiagnosis and undertreatment are prevalent; however, newer formulations and combination therapies increase market penetration.

3. Competitive Landscape and Key Players

Competitor	Main Products	Market Share	R&D Focus
GSK	Symbicort (budesonide/formoterol)	~25%	Fixed-dose combinations
AstraZeneca	Pulmicort, Symbicort	~20%	LABA, ICS, LAMA innovations
Novartis	Ultibro Breezhaler (glycopyrrolate/ indacaterol)	~15%	LAMA/LABA combos

Implication: Entry with novel formulation or delivery method could exploit unmet needs.

---

Financial Trajectory and Investment Analysis

1. Revenue Projections

Year	Estimated Annual Revenue (USD Million)	Assumptions
2023	500	Launch of new combination or expanded indication
2024	700	Increased market penetration, insurance coverage
2025	1,050	Broader adoption, potential label expansion
2026	1,400	Steady growth, regional expansion
2027	1,800	Peak market capture, competitive positioning

Source: Analyst estimates, historical growth trends, and pipeline development data.

2. Cost Structure and Margins

Cost Component	Estimated % of Revenue	Details
R&D	15-20%	Pipeline expansion, formulation optimization
Manufacturing	10-12%	Inhaler device production, contract manufacturing
Marketing & Sales	25-30%	Market access, medical education, promotion
General & Administrative	8-10%	Operations, compliance, licensing
Overall Gross Margin	65-70%	Due to high-margin inhalation products

3. Investment Considerations

• Development pipeline risk: Potential delays in formulation optimization or regulatory approval.
• Pricing and reimbursement: Variability across regions could impact revenues.
• Patent landscape: Patent expiration of key products (e.g., GSK’s Symbicort in 2026) would open generics markets.
• Regulatory environment: Stringent approval pathways, especially for combination drugs.

---

Regulatory and Policy Environment Impact

Regulation/Policy	Impact on Market	Key Notes
Pharmacovigilance Requirements	Increased safety monitoring costs	FDA, EMA mandates for post-market safety
Patent Laws	Affects exclusivity periods	Patent expiry timelines impact generic entry
Reimbursement Policies	Market access affordability	Variability across countries may influence sales volume
COVID-19 Impact	Supply chain disruptions, accelerated inhaler adoption	Transition towards respiratory product resilience

Sources: FDA, EMA regulatory updates (2022-23).

---

Comparative Analysis: Market Position of the Combination Therapy

Attribute	Budesonide + Formoterol	Budesonide + Formoterol + Glycopyrrolate	Competitor Products
Indication Spectrum	COPD, asthma	COPD, asthma	COPD (e.g., Spiriva, Ultibro)
Delivery Devices	DPI, MDI	DPI, MDI	DPI, nebulizers
Therapeutic Uniqueness	Established combination	Adds LAMA for enhanced bronchodilation	Similar, but with differing LAMA components
Price Point	Mid-range	Slightly higher due to triple therapy	Competitive with existing combos

Implication: Combining three active ingredients could capture niche segments and improve patient adherence, translating into revenue growth.

---

Strategic Opportunities & Risks

Opportunities:

• Formulation innovations: Novel inhaler devices with improved delivery.
• Label expansion: New indications, e.g., eosinophilic asthma.
• Market penetration: Developing regions with growing respiratory disease burden.
• Partnerships: Licensing, co-marketing deals with established players.

Risks:

• Generic competition: From patents expiring on existing products.
• Regulatory hurdles: Delays or rejections affecting timely market entry.
• Market saturation: Limited room for growth if existing therapies dominate.
• Pricing pressures: Policymaker initiatives to reduce healthcare costs.

---

Key Takeaways

• The inhalation therapy market focusing on COPD and asthma is projected to grow at a CAGR of approximately 5.2%, driven by epidemiological trends and technological advances.
• A combination of budesonide, formoterol fumarate, and glycopyrrolate holds strategic positioning for capturing patient segments seeking effective triple therapy options.
• Revenue projections indicate potential for significant growth post-launch, contingent on regulatory approval, market access, and competitive differentiation.
• Patent expiry cycles and evolving regulatory frameworks remain critical factors influencing long-term profitability.
• Companies investing in formulation innovation, pipeline expansion, and regional market development can maximize returns, but must vigilantly monitor generics, pricing, and policy shifts.

---

FAQs

Q1: What are the primary therapeutic advantages of combining budesonide, formoterol fumarate, and glycopyrrolate?
Answer: The combination offers dual bronchodilation and anti-inflammatory effects, targeting multiple pathways in obstructive airway diseases, potentially improving symptom control, reducing exacerbations, and enhancing patient adherence through simplified regimens.

Q2: How does the patent landscape impact investment in this combination?
Answer: Patent expiries on key components and formulations open opportunities for generics, which can erode market share and revenues of innovator products. Strategic timing of pipeline development and patent filings is vital to maximize exclusivity periods.

Q3: What are the key regulatory challenges faced by combination inhalers?
Answer: Regulatory agencies require demonstration of safety, efficacy, and bioequivalence, especially for fixed-dose combinations. Additional complexity arises from device approval, stability concerns, and label expansions.

Q4: Which regional markets are expected to contribute most to revenue growth?
Answer: North America remains the largest market, followed by Europe and Asia-Pacific, with the latter exhibiting the fastest growth driven by increasing disease prevalence and healthcare infrastructure development.

Q5: What innovations could disrupt the current market for this drug combination?
Answer: Advances such as smart inhalers with digital tracking, novel drug delivery systems, and personalized medicine approaches could redefine treatment paradigms and market shares.

---

References

[1] IQVIA. (2023). Global Respiratory Market Forecast.
[2] WHO. (2018). Asthma Fact Sheet.
[3] U.S. Food and Drug Administration. (2022). Drug Approvals & Regulatory Information.
[4] EMA. (2023). Respiratory Medicines Policy.
[5] MarketResearch.com. (2023). Global COPD and Asthma Treatment Market.